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Abstract
Background: In randomized, controlled trials, antidepressant medications have been shown to
reduce the duration of major depressive episodes and to reduce the frequency of relapse during
long-term treatment. The epidemiological impact of antidepressant use on episode duration and
relapse frequency, however, has not been described.
Methods: Data from two Canadian general health surveys were used in this analysis: the National
Population Health Survey (NPHS) and the Canadian Community Health Survey (CCHS). The NPHS
is a longitudinal study that collected data between 1994 and 2000. These longitudinal data allowed
an approximation of episode incidence to be calculated. The cross-sectional CCHS allowed
estimation of episode duration. The surveys used the same sampling frame and both incorporated
a Short Form version of the Composite International Diagnostic Interview.
Results: Episodes occurring in antidepressant users lasted longer than those in non-users. The
apparent incidence of major depressive episodes among those taking antidepressants was higher
than that among respondents not taking antidepressants. Changes in duration and incidence over
the data collection interval were not observed.
Conclusions: The most probable explanation for these results is confounding by indication and/
or severity: members of the general population who are taking antidepressants probably have more
highly recurrent and more severe mood disorders. In part, this may have been due to the use of a
brief predictive diagnostic interview, which may be prone to detection of sub-clinical cases.
Whereas antidepressant use increased considerably over the data-collection period, differences in
episode incidence and duration over time were not observed. This suggests that the impact of
antidepressant medications on population health may have been less than expected.
Background
Depressive disorders are among the most important con-
tributors to disease burden at the population level http://
www.who.int/whr2001/2001/. While primary prevention
for this condition has remained an elusive goal, provision
of treatment has been viewed as having the capacity to
reduce its impact on population health. Randomized,
controlled clinical trials confirm that treatment with anti-
depressant medications can favorably impact the course
of major depressive disorder. Clinical practice guidelines
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recommend acute treatment to reduce episode duration,
continuation treatment to prevent relapse and mainte-
nance treatment for those at high risk of recurrence [1].
Direct generalization of clinical trial data to the general
population results in an expectation that depressive epi-
sode frequency and episode duration should be reduced
in those receiving antidepressant treatment. However,
outcomes reported in clinical trials are not necessarily
reflected in "real world" outcome data. Since treatments
are not assigned randomly in clinical settings, those
treated are likely to have more severe illness (both in
terms of episode duration and recurrence risk) than those
who do not seek or receive treatment. In such circum-
stances, the effect of treatment may become confounded
with the effect of the underlying disorder itself, and/or its
severity [2].
Despite the plausible occurrence of confounding by indi-
cation and confounding by severity, population-based
studies examining outcomes in relation to treatment sta-
tus in the general population have not been reported. The
objective of the current study was to estimate the inci-
dence and duration of major depressive episodes in mem-
bers of the general population who are receiving or not
receiving antidepressant treatment.
Methods
The National Population Health Survey (NPHS) is a lon-
gitudinal general health survey conducted by the Cana-
dian government's statistical agency, Statistics Canada
http://www.statcan.ca. The NPHS sample consists of
17,262 subjects selected in 1994 and 1995 (hereafter
denoted 1994/95) who have been followed prospectively
with interviews every two years since. Data has been
released for the first four cycles (1994/95 to 2000/01).
The Canadian Community Health Survey (CCHS) is
another general health survey conducted by Statistics Can-
ada. The CCHS has a very large sample size (n = 130,880)
and employed a cross-sectional study design. Data collec-
tion for the CCHS occurred in 2000.
Both the NPHS and the CCHS utilized probability sam-
ples, based on the same sampling frame, from the Cana-
dian general population. The sampling procedures
incorporated both clustering and unequal selection prob-
abilities. Valid inference therefore requires the use of sam-
pling weights and statistical procedures accounting for
non-independence within clusters. In order to deal with
these methodological issues, a bootstrap procedure for
variance estimation developed by Statistics Canada was
employed in this analysis. This procedure accounts for the
design effects.
Both the NPHS and the CCHS recorded medication use
with a series of self-report items. The item relevant to this
analysis asked whether the respondent had taken antide-
pressant medications during the month preceding the
interview. Each interview also included the Composite
International Diagnostic Interview Short Form for Major
Depression (CIDI-SFMD), which was developed and vali-
dated by Kessler et al. [3]. This is a brief, fully structured
instrument derived from a set of modified CIDI items. The
CIDI-SFMD was designed to provide an operationaliza-
tion of the DSM-IV [4] diagnostic criteria for major
depression and is sufficiently brief that it can be included
in general health surveys. The instrument detects symp-
toms indicative of major depression, and identification of
five such symptoms (one of which must be depressed
mood or loss of interest) indicates a high probability that
the subject fulfilled DSM-IV criteria for major depression
in the 12-months preceding the interview. It should be
noted, however, that the Short Form does not contain all
of the clinical significance probes and organic exclusion
items that are included in the full CIDI, and may therefore
detect some subclinical episodes [5]. A component of the
CIDI-SFMD is an item that asks (of subjects reporting a
probable episode of major depression) the number of
weeks in the preceding year that were characterized by
depressive symptoms.
In calculating incidence, pairs of observations across
NPHS longitudinal data collection cycles were used. There
were three suitable intervals covered by the four data col-
lection rounds: 1994/95 to 1996/97, 1996/97 to 1998/99
and 1998/99 to 2000/01.
Attrition rates have generally been modest in the NPHS,
with 76.6% of subjects having been successfully followed
over the first four cycles [6]. In each instance, the subjects
with major depression at the baseline interview were
excluded and the remaining subjects were regarded as the
population at risk of having a new or recurrent episode. It
was not possible to differentiate between new and recur-
rent episodes, as lifetime history was not available. The
proportion of subjects not reporting an episode in the 12-
months preceding an interview who subsequently
reported an episode in the 12-months preceding their
interview 2 years later was used as an approximation of
episode incidence. With the four available NPHS cycles,
incidence could be estimated in this way across the three
intervals.
Results
Estimates of the number of weeks depressed in the past
year derived from the CCHS were computed from
126,715 subjects who provided valid responses both to
the CIDI-SFMD (including the duration item) and the
antidepressant use survey item. There were 9729 subjectsPopulation Health Metrics 2004, 2:9 http://www.pophealthmetrics.com/content/2/1/9
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with an episode of major depression in the year preceding
the interview and 9508 (97.7%) of these provided valid
duration data. Figure 1 shows the number of weeks
depressed in the past year as reported by subjects with
major depression in the CCHS, depending on whether or
not they were taking antidepressants. Weeks depressed in
the past year is presented in Figure 1 as a cumulative fre-
quency; the Figure depicts the proportion (on the 'y' axis)
of subjects reporting a duration less than or equal to the
number of weeks specified (on the 'x' axis). Figure 1 shows
that subjects reporting antidepressant use had a greater
number of weeks depressed in the year preceding the
interview. Analogous plots were generated for the each of
the NPHS cycles, and each presented a similar pattern. Fig-
ure 2 presents weeks depressed in the past year from the
1994/95 NPHS. In the CCHS, the mean reported number
of weeks depressed in the past year was 10.8 weeks among
those not taking antidepressants and 18.7 weeks among
subjects who reported taking antidepressants.
Figure 3 presents the weeks depressed in the past year data
from the NPHS and CCHS, without reference to antide-
pressant use. The reported weeks depressed in the past
year is virtually identical in each of the four NPHS data
collection cycles and the CCHS.
Table 1 presents approximate episode incidence, as calcu-
lated for the three intervals between the four NPHS data
collection interviews. The point estimate for the 1996/97
to 1998/99 interval was slightly lower than the other two,
Cumulative proportion reporting ≤ specified number of weeks depressed in the past year for CIDI-SFMD positive subjects (n =  9508) in the Canadian Community Health Survey, by antidepressant use Figure 1
Cumulative proportion reporting ≤ specified number of weeks depressed in the past year for CIDI-SFMD positive subjects (n = 
9508) in the Canadian Community Health Survey, by antidepressant use.
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but the confidence intervals associated with these esti-
mates suggest that this difference could be due to chance.
The incidence of new episodes in subjects reporting the
use of antidepressant medication was approximately three
times that of subjects not using antidepressants.
Discussion
Direct generalization of clinical trial data to the general
population would lead to an expectation that subjects in
the general population who report antidepressant treat-
ment should have briefer episodes of major depression
than those who do not receive such treatment. Similarly,
one might hypothesize that subjects reporting antidepres-
sant treatment should have a reduced incidence of epi-
sodes. In the current analysis of national survey data,
neither expectation was found to hold true. Subjects
reporting an episode of major depression and reporting
receipt of antidepressant treatment reported more, rather
than fewer, weeks depressed in the preceding year.
Similarly, subjects who did not have an episode of major
depression in the year preceding an interview but who
nevertheless reported using antidepressant medications
had a higher risk of having an incident episode than sim-
ilar subjects who did not report taking antidepressants.
The most obvious explanation for these findings is that of
confounding by indication or severity.
Some of these results may have been due to inadequacies
involving the data sources. One of these is the brief, and
therefore somewhat crude [5] nature of the CIDI-SFMD as
Cumulative proportion reporting ≤ specified number of weeks depressed in the past year for CIDI-SFMD positive subjects (n =  1030) in the 1994/95 National Population Health Survey, by antidepressant use Figure 2
Cumulative proportion reporting ≤ specified number of weeks depressed in the past year for CIDI-SFMD positive subjects (n = 
1030) in the 1994/95 National Population Health Survey, by antidepressant use.
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Proportion with ≤ specified weeks depressed in past year, by year of data collection Figure 3
Proportion with ≤ specified weeks depressed in past year, by year of data collection.
Table 1: Approximate incidence* in subjects taking or not taking antidepressants in the baseline year
Baseline year Follow-up interview Taking antidepressants Not taking antidepressants
Approximate 
incidence* 
(unweighted 
proportion)
95% confidence 
interval
Approximate 
incidence* 
(unweighted 
proportion)
95% confidence 
interval
1994 1996 12.7% (20/172) 6.0 – 19.4 3.4% (277/9055) 2.9 – 4.0
1996 1998 7.8% (21/234) 3.5 – 12.0 3.5% (375/9127) 3.0 – 4.1
1998 2000 12.7% (47/352) 8.6 – 16.8 3.5% (317/8994) 2.9 – 4.0
Average 11.1% 3.5%
*Proportion of subjects free from a major depressive episode in the year preceding the baseline interview who developed major depression in the 
year preceding the follow-up interview. These estimates are weighted to account for design effects. The unweighted raw proportions have been 
placed beside the weighted estimates.
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a measure of major depression. As this instrument does
not contain detailed clinical significance probes, some
sub-clinical episodes may have been detected. As the
CIDI-SFMD does not contain organic exclusions, the
instrument may have detected some episodes character-
ized by organic symptoms. The 12-month prevalence of
major depression in the CCHS was 7.4% which is higher
than most recently published estimates of major depres-
sion prevalence, consistent with the possibility of non-
specificity. This draws into question whether these results
would be replicated with the use of a more detailed diag-
nostic instrument. However, this concern should not be
overstated. Some studies using the full CIDI have reported
higher estimated 12-month prevalence [7,8]. Severe
depressive disorders that are treated with antidepressants
may have longer episode durations and higher relapse
rates than less severe and untreated disorders.
Items evaluating antidepressant use in each survey
referred to use of the medications during the past month,
whereas probable major depressive episodes occurring
during the past year are detected by the CIDI-SFMD.
Therefore, even though subjects who reported taking anti-
depressants were found to be more likely to have a subse-
quent episode of major depression, the data did not allow
a determination of whether some of these subjects may
have stopped or started antidepressants at some time dur-
ing the follow-up interval.
Another limitation of the data sources used in this project
was the lack of comorbidity data. Many of the subjects tak-
ing antidepressants may have been doing so for indica-
tions such as the prophylaxis of migraine headaches or for
treatment of anxiety disorders. Both migraine headaches
[9,10] and anxiety disorders [11] are frequently associated
with major depression. To the extent that these disorders
impact upon the risk and prognosis of major depressive
episodes, they could also confound associations between
antidepressant use, major depression episode incidence
and episode duration.
While confounding by indication and severity offer, per-
haps, the most appealing explanation for these results it is
important to emphasize that the attractiveness of these
explanations is based on a set of assumptions: that antide-
pressants are efficacious in reducing episode duration and
the risk of relapse and recurrence. An altered set of initial
assumptions leads to other possible interpretations. For
example, some authors have hypothesized that antide-
pressant treatment may lead to a deterioration in the long-
term course of mood disorders [12]. This hypothesis,
although not widely accepted, predicts that episode dura-
tion and incidence would be higher in those reporting
antidepressant use than in those not using these medica-
tions. A finding consistent with this idea was a meta-anal-
ysis by Baldessarini et al., which found that subjects taking
antidepressant medications for longer periods were more
likely to relapse upon discontinuation [13].
Generally, the public health challenges associated with
major depression have been conceptualized in "common
sense" terms, and in a way that does not depend on under-
lying etiological features of the disorder. For example, the
idea that preventing relapse (episode incidence) should
translate into reduced prevalence and reduced disease
burden seems on the surface to be a common-sense belief.
However, it has been hypothesized that depression can
assume an adaptive role [14]. If an adaptive role for
depression involves, for example, limiting an individual's
interaction with a stressful environment (e.g. if depressive
symptoms serve the adaptive purpose of discouraging
interaction with elements of the environment that trigger
them), then treatment of depression may indirectly lead
to increased stress exposure. If this is true, then antide-
pressant treatment may increase people's comfort and
capacity to function in a stressful environment, but may
also increase the intensity of stress in the environment
that surrounds them. Such complex dynamics could
obscure an expected decline in prevalence due to
increased treatment.
Conclusions
Most of the literature concerned with major depression
and public health has emphasized that the disorder is
under-treated, although more recent studies have begun
to move beyond the frequency of treatment to address the
issue of treatment adequacy [15]. There is an emerging
need to address the lack of epidemiological evidence con-
firming the population-health benefits of increased anti-
depressant treatment. Specifically, it will be necessary to
determine the extent to which negative outcomes in asso-
ciation with antidepressant treatment in observational
data sources represent a methodological artifact.
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DSM-IV Diagnostic and Statistical Manual of Mental Dis-
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